Search hospitals > Kentucky > Louisville
James Graham Brown Cancer Center
Claim this profileLouisville, Kentucky 40202
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Melanoma
Conducts research for Pancreatic Cancer
Conducts research for Squamous Cell Carcinoma
297 reported clinical trials
22 medical researchers
Summary
James Graham Brown Cancer Center is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lung Cancer, Breast Cancer, Melanoma, Pancreatic Cancer, Squamous Cell Carcinoma and other specialties. James Graham Brown Cancer Center is involved with conducting 297 clinical trials across 277 conditions. There are 22 research doctors associated with this hospital, such as Neal E. Dunlap, Rebecca Redman, MD, Robert C. Martin, MD,PhD,FACS, and Mohamed M. Hegazi.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
Top PIs
Neal E. DunlapThe James Graham Brown Cancer Center at University of Louisville4 years of reported clinical research
Studies Squamous Cell Carcinoma
Studies Lung Cancer
19 reported clinical trials
45 drugs studied
Rebecca Redman, MDJames Graham Brown Cancer Center1 year of reported clinical research
Studies Squamous Cell Carcinoma
Studies Cancer
16 reported clinical trials
29 drugs studied
Robert C. Martin, MD,PhD,FACSUniversity of Louisville7 years of reported clinical research
Studies Pancreatic Cancer
Studies Liver Cancer
11 reported clinical trials
18 drugs studied
Mohamed M. HegaziThe James Graham Brown Cancer Center at University of Louisville8 years of reported clinical research
Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
10 reported clinical trials
33 drugs studied
Clinical Trials running at James Graham Brown Cancer Center
Skin Cancer
Lung Cancer
Breast Cancer
Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Breast cancer
Small Cell Lung Cancer
Ovarian Cancer
Cemiplimab + Surgery
for Advanced Skin Cancer
This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.
Recruiting2 awards Phase 37 criteria
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Lifileucel + Pembrolizumab
for Melanoma
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossover period.
Recruiting2 awards Phase 37 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at James Graham Brown Cancer Center?
James Graham Brown Cancer Center is a medical facility located in Louisville, Kentucky. This center is recognized for care of Lung Cancer, Breast Cancer, Melanoma, Pancreatic Cancer, Squamous Cell Carcinoma and other specialties. James Graham Brown Cancer Center is involved with conducting 297 clinical trials across 277 conditions. There are 22 research doctors associated with this hospital, such as Neal E. Dunlap, Rebecca Redman, MD, Robert C. Martin, MD,PhD,FACS, and Mohamed M. Hegazi.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.